Background Despite availability of international evidence-based guidelines for osteoarthritis
(OA) management, agreement on the different treatment modalities is lacking. Method A …

Updated guidelines from the Osteoarthritis Research Society International and the UK's
National Institute for Health and Care Excellence provide a clear summary of the evidence …

Osteoarthritis (OA) can be a progressive, disabling disease, leading to diminished quality of
life, and, for over 500,000 individuals annually in the US, total joint replacement. The …

Epidemiologic and clinical research in osteoarthritis (OA) continues to focus on analytic and
descriptive epidemiology, and the role of both nonpharmacologic and pharmacologic …

Objective To summarize proceedings of a workshop convened to discuss advances in
disease modifying osteoarthritis (OA) drugs and regulatory challenges in bringing these …

Alleviation of pain and inhibition of inflammation are the primary goals of pharmacotherapy
of osteoarthritis (OA). These therapeutic goals can almost always be accomplished by the …

Osteoarthritis is the most common chronic joint disease characterized by progressive
damage to the joints, leading to pain and loss of function. There is currently no cure or …

Osteoarthritis (OA) is the most common joint disease in the world, with an age-associated
increase in both incidence and prevalence. Clinical and epidemiologic research is crucial to …

There is a big need for the development of novel therapies for the safe management of
chronic pain associated with OA. Here we reviewed PubMed (2015 onward) and …

OBJECTIVE: To respond to a pre-specified set of questions posed by the United States Food
and Drug Administration (FDA) on defining the disease state to inform the clinical …